Cancer Biology Lab

Lab News

  • Hye-Kyung's paper was published in the Journal of Medicinal Chemistry TITLE: Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.ABSTRACT:Although Hsp90 inhibitors can inhibit multiple tumorigenic pathways in cancer cells, their anticancer activity has been disappointingly modest. However, by forcing Hsp90 inhibitors into the mitochondria with mitochondrial delivery vehicles, they were converted into potent drugs targeting the mitochondrial Hsp90 paralog TRAP1. Here, to improve mitochondrial drug accumulation without using the mitochondrial delivery vehicle, we increased freely available drug concentrations in the cytoplasm by reducing the binding of the drugs to the abundant cytoplasmic Hsp90. After analyzing X-ray cocrystal structures, the purine ring of the Hsp90 inhibitor 2 (BIIB021) was modified to pyrazolopyrimidine scaffolds. One pyrazolopyrimidine, 12b (DN401), bound better to TRAP1 than to ...
    Posted Sep 29, 2017, 11:32 AM by Byoung Heon Kang
  • Development of TRAP1 inhibitor (KDDF Interview) [UNIST] 새로운 기전으로 작용하는 항암 약물 개발 ‘도전’
    Posted Jun 7, 2016, 3:27 AM by Byoung Heon Kang
Showing posts 1 - 2 of 14. View more »

Research Area

1) Cellular functions and molecular regulatory mechanism of the mitochondrial chaperone TRAP1.

2) TRAP1 and Client networks: implications for human diseases (Cancer & beyond)

3) Development of TRAP1 inhibitors as anticancer drugs: mitochondria-targeted "SMTINs" and in vivo pan-Hsp90 inhibitor "Panvotinibs".

4) Cancer stem cells and mechanism of resistance to chemo- and radio-therapies.

5) Tumor microenvironment: tumor cross-talk with inflammation and metabolism.

Position Available

[대학원생 및 UNIST 학부인턴쉽]

다음의 연구를 함께할 대학원생 및 인턴쉽 학생을 모집합니다. 

1) 뇌종양 암줄기세포에서의 와버그효과 (Warburg effect)와 에너지 대사조절의 분자기전 연구: 암대사와 종양의 형성, 성장 및 전이와의 연관성을 규명하여  새로운 항암치료전략을 제시하는 것을 목표함.

2) 대사성질환에서의 미토콘드리아 기전연구: 대사성질환(당뇨 및 관련질환)에서 미토콘드리아 변성기전 분석 및 미토콘드리아를 타겟으로 하는 치료전략을 검증하여 경구용 치료제 개발.

3) 혁신항암신약 및 난치질환치료제 개발: 다학제간 협력연구를 통하여, 암을 비롯한 난치질환 환자치료에 사용될 수 있는 혁신형치료제 도출 (약물개발단계중 전임상 완료 및 IND filing을 목표로 함). 생명과학자로써 약물개발의 방향과 전략을 제시하고, 합성된 약물의 약효를 평가하며, 약물기전을 분석함.